{"disease":{"id":"atypical-hemolytic-uremic-syndrome-ahus","name":"atypical hemolytic uremic syndrome ahus"},"drugs":{"marketed":[{"drug_id":"ravulizumab","indication_name":"Atypical hemolytic uremic syndrome (aHUS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultomiris","generic_name":"RAVULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitor [EPC]","quality_score":75,"revenue":"5100","mechanism":"Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells."},{"drug_id":"eculizumab-aeeb","indication_name":"Atypical Hemolytic Uremic Syndrome (aHUS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BKEMV","generic_name":"ECULIZUMAB-AEEB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Complement Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"ravulizumab-cwvz","indication_name":"Atypical hemolytic uremic syndrome (aHUS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ULTOMIRIS","generic_name":"RAVULIZUMAB-CWVZ","company_name":"ALEXION PHARM","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ultomiris","indication_name":"Atypical hemolytic uremic syndrome (aHUS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ultomiris","company_name":"Alexion Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06099236","title":"A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":367,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06312644","title":"Study of Ultomiris® (Ravulizumab) Safety in Pregnancy","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02949128","title":"Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03131219","title":"Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01770951","title":"A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT01757431","title":"The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}